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We generated a mouse line harboring an autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) mutation: the 4 nicotinic
receptor S248F knock-in strain. In this mouse, modest nicotine doses (1–2 mg/kg) elicit a novel behavior termed the dystonic arousal
complex (DAC). The DAC includes stereotypical head movements, body jerking, and forelimb dystonia; these behaviors resemble some
core features of ADNFLE. A marked Straub tail is an additional component of the DAC. Similar to attacks in ADNFLE, the DAC can be
partially suppressed by the sodium channel blocker carbamazepine or by pre-exposure to a very low dose of nicotine (0.1 mg/kg). The
DAC is centrallymediated, genetically highly penetrant, and, surprisingly, not associatedwith overt ictal electrical activity as assessed by
(1) epidural or frontal lobe depth-electrode electroencephalography or (2) hippocampal c-fos-regulated gene expression. Heterozygous
knock-inmice are partially protected fromnicotine-induced seizures. The noncompetitive antagonistmecamylamine does not suppress
the DAC, although it suppresses high-dose nicotine-inducedwild-type-like seizures. Experiments on agonist-induced 86Rb and neuro-
transmitter efflux from synaptosomes and on 4S248F2 receptors expressed in oocytes confirm that the S248F mutation confers
resistance tomecamylamine blockade. Genetic background, gender, andmutant gene expression levelsmodulate expression of the DAC
phenotype in mice. The S248F mouse thus appears to provide a model for the paroxysmal dystonic element of ADNFLE semiology. Our
model complements what is seen in other ADNFLE animal models. Together, these mice cover the spectrum of behavioral and electro-
graphic events seen in the human condition.
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Introduction
Nocturnal frontal lobe epilepsy (NFLE) is characterized by clus-
ters of stereotypic episodes of arousal from sleep associated with
dystonic neck, limb, and trunk movements that occur during
stages 2–4 of non-rapid eye movement (REM) sleep (Montagna,
1992; Plazzi et al., 1995; Provini et al., 1999; Provini et al., 2000).
Less commonly, there are prolonged ballistic limb and trunk
movements, resulting in injury (Scheffer et al., 1995; Combi et al.,
2004). Autosomal-dominant NFLE (ADNFLE) (Scheffer et al.,
1995), a familial subtype of NFLE, was initially associated with a
missense (S248F) mutation in the 4 nicotinic acetylcholine re-
ceptor subunit (4-nAChR) gene (Steinlein et al., 1995) at posi-
tion 6 in the M2 transmembrane region. Subsequently, in other
ADNFLE pedigrees, additional mutations were discovered at the
4 M2–10 (Steinlein et al., 1997; Hirose et al., 1999), M2–17
(Steinlein et al., 1997;Hirose et al., 1999), and2 subunitM2–22
positions and one at the2M3 position that contactsM2 inmost
structural models (De Fusco et al., 2000; Phillips et al., 2001;
Bertrand et al., 2005). A mutation in 2 (Aridon et al., 2006) was
identified in a pedigree with atypical nocturnal epilepsy.
Electrophysiological analyses of heterologously expressed
ADNFLE alleles suggest that ADNFLEmutant receptors display a
gain of function (Bertrand et al., 2002; Rodrigues-Pinguet et al.,
2003, 2005). Two mouse strains with extreme gain-of-function
mutations in 4 at the M2–9 position (not linked to ADNFLE)
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were generated. Adult 9 knock-inmice do not display spontane-
ous seizures (Fonck et al., 2003, 2005) but are hypersensitive to
many effects of nicotine. The reported L9A mutant low-dose
nicotine-induced “behavioral seizures” are not associated with
epileptiform spike-and-wave electroencephalographic (EEG)
changes (Fonck et al., 2005); in this respect, the L9A nicotine-
induced behavior resemblesmost ADNFLE attacks (Combi et al.,
2004).
Two ADNFLE knock-in strains have been described: the
Chrna4S252F (same as our S248F M2–6 mutation) and the 4
in-frame insertion of a leucine at M2–17 (Klaassen et al., 2006).
Both lines display spontaneous seizures of two types: brief peri-
ods of behavioral arrest and extended attacks of wild running
associated with falls. In contrast to typical ADNFLE seizures,
which display epileptiform electroencephalograms in only one-
third of patients (Combi et al., 2004), thesemice display frequent
spontaneous seizures associated with high-voltage EEG spikes
throughout the day. However, ADNFLE includes a spectrum of
clinical manifestations. Although brief dystonic “extrapyrami-
dal” semiology is a signature of ADNFLE (Scheffer et al., 1995;
Combi et al., 2004; Bertrand et al., 2005), occasional patients
display violent, prolonged hyperkinetic activity (Scheffer et al.,
1995). Thus, the Klaassen lines could represent a more severe
model of ADNFLE.
Here we report that4 S248F knock-inmice respond tomod-
est nicotine injections with a novel behavior that closely resem-
bles the dystonic head and limb semiology of ADNFLE attacks
(Scheffer et al., 1995; Combi et al., 2004). Consonant with the
majority of ADNFLE attacks in humans (Combi et al., 2004), the
dystonic paroxysms in S248Fmice are not accompanied by overt
epileptiform changes.
Materials andMethods
Materials. [ 3H]Dopamine (40–60Ci/mmol), [ 3H]GABA (35Ci/mmol),
86Rb, and [125I]epibatidine were obtained from PerkinElmer (Boston,
MA). All reagent-grade salts and the following chemicals were products
of Sigma-Aldrich (St. Louis, MO): acetylcholine iodide, ascorbic acid,
atropine sulfate, bovine serum albumin, carboxymethoxylamine (ami-
nooxyacetic acid), cytisine, diisophosphofluorophosphate, glucose,
NNC-711, nomifensine, pargyline, and tetrodotoxin. HEPES was from
Roche Diagnostics (Indianapolis, IN), and sucrose was from Fisher
Chemical (Fairlawn, NJ). Mecamylamine used in synaptosome assays
was a gift from Merck, Sharp and Dohme Research Lab (Rahway, NJ).
Mecamylamine, carbamazepine, 2-hydroxypropyl--cyclodextrin, and
nicotine used in behavioral studies were obtained from Sigma (St. Louis,
MO); nicotine doses stated refer to free base. Chlorisondamine diiodide
was obtained from Tocris (Ellisville, MO). Chloral hydrate was obtained
from Crown Scientific (Melbourne, Australia). Mecamylamine used in
the oocyte study was obtained from Sigma.
Animals.All procedures involving the use of live animals conformed to
the Australian National Health and Medical Research Council code of
practice. The guidelines of the National Institutes of Health (NIH) were
followed for all animal procedures at the University of Colorado and the
California Institute of Technology.
Generation of S248F knock-in mice. An4000 bp fragment containing
exon 5 of the 4-nAChR was excised from the L9S targeting construct
(Labarca et al., 2001) using an SpeI restriction site and cloned into pBlue-
Script (Stratagene, La Jolla, CA). Site-directed mutagenesis was per-
formed using the QuikChange site-directedmutagenesis kit (Stratagene)
to correct the original L9Smutation and introduce the S248Fmutation.
Primers used for mutagenesis reaction were a 40 bp sense
5-AGGTCACGCTGTGCATCTTTGTGCTGCTTTCTCTCACCGT-3
and 40 bp antisense 5-ACGGTGAGAGAAAGCAGCACAAAG-
ATGCACAGCGTGACCT-3. The 4000 bp SpeI fragment containing
the S248F mutation was recloned into the targeting construct backbone.
The final targeting construct was a 15.2 kb plasmid containing the S248F
carrying exon 5 with a LoxP-flanked neomycin phosphotransferase-
resistance cassette cloned 163 bp downstream of exon 5. The diphtheria
toxin-A chain gene is cloned adjacent to the 5-flanking homologous
limb for negative selection against random insertion. The construct was
linearized with NotI and electroporated into a 129/Sv line of embryonic
stem (ES) cells (W9.5). Homologous recombinant events were identified
by an EcoRI/BamHI digest Southern blot using an 1000 bp flanking
probe complementary to a genomicDNA sequence lying upstreamof the
5 homologous flank. The wild-type (WT) allele was identified as a 9.7 kb
BamHI–BamHI fragment, whereas the recombinant allele was a 7.7 kb
BamHI–EcoRI fragment (see Fig. 1A). Recombinant ES clones identified
by Southern blotting and confirmed to have the S248F knock-in muta-
tion by direct sequencing were injected into C57BL/6 blastocysts for
generation of chimeric mice. Chimeras that were consistently germline
transmitting were mated with CD1 background adenovirus EIIa
promoter-driven Cre recombinase-expressing homozygous transgenic
mice (Lakso et al., 1996) so as to excise the neomycin selection cassette.
The presence of the mutation at the RNA level was verified by extracting
total-brain RNA, synthesizing cDNA using the First-Strand cDNA syn-
thesis kit (Invitrogen, San Diego, CA) and sequencing amplicons gener-
ated by PCR. Heterozygous CD1/129Sv background mice were crossed
with each other to generate homozygous mice or were mated with
C57BL/6mice to generatemice on a C57BL/6 genetic background.High-
percentage chimeras were also mated with pure 129Sv background WT
mice (Howard Florey Institute) to generate neomycin intact heterozy-
gous 129Sv background mice, and these were used in crosses with EIIa/
Cre activator lines when chimeras were no longer generating progeny.
PCR using sequence-specific primers that were based on the sequence of
the original L9S plasmid (Labarca et al., 2001) spanning the residual
LoxP site were used to identify transgenic progeny. Forward primerswith
the sequence 5-GAGGGTACATAGTGTAGTCT-3 and a backward
primer with the sequence 5-AAACAGCCTGAACACT-TCAA-3 were
used.
EEG monitoring of mice. Mice were anesthetized with chloral hydrate
(4.0%, 0.01ml/g). Four electrodeswere fitted onto a plastic cap to occupy
the following position on a mouse skull: front right and left, 1.5 mm
anterior to bregma and 1.5mm lateral to themidline; posterior right and
left, 3mmposterior to bregma and 1.5mm lateral to themidline (Frank-
lin and Paxinos, 1997). The cap and electrodes were secured to themouse
skull using dental cement. The mice were allowed to recover from the
procedure for at least 2 weeks before EEG recordings commenced. The
potential difference (voltage) between two frontal electrodes was re-
corded as the anterior EEG channel, whereas the difference between the
two posterior electrodes was recorded as the posterior EEG channel. A
Molecular Devices Digi-Data programmable signal conditioner and Cy-
berAmp 380 were connected to a Pentium 4 personal computer (PC) to
record EEG data. Both the anterior and posterior channels were sampled
at 1 kHz with bandpass filtering at 1–80 Hz. Mice were monitored for
baseline changes and for evidence of spontaneous electrographic seizures
both during extended daytime and overnight as described below. Five
minutes of baseline electroencephalograms were recorded before nico-
tine was administered intraperitoneally. All postinjection behavior was
monitored with a camera attached to the PC. Electroencephalogram and
video scorers were blinded to the genotype of the mice.
Combined depth and epidural electrode EEG studies. Simultaneous epi-
dural and depth-electrode video–electroencephalogram recordings were
conducted on eight adult female heterozygous CD1/129 genetic back-
ground S248F knock-inmice (24–29 g), and each animal wasmonitored
between the hours of 10:00 A.M. and 5:00 P.M. for at least 10 h over a 2 d
period. Mice were anesthetized by intraperitoneal injection with a mix-
ture of ketamine (60mg/kg; Parnell Laboratories, Alexandra, New South
Wales, Australia) and xylazine (10mg/kg; Troy Laboratories, Smithfield,
New SouthWales, Australia), and their temperature was monitored and
maintained using a heated blanket (Frederick Haer Company, Bowdoin-
ham,ME).Mice were placed in amouse-adapted stereotaxic frame (My-
NeuroLab, St. Louis, MO) in a flat skull position. Monopolar electrodes
made of insulated silver wire (0.125 mm in diameter) were implanted in
the left ventral orbital cortex (VO). The VO is located 2.1mm anterior to
bregma, 0.9mm lateral tomidline, and 2.7mmdorsoventral as described
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previously (Franklin and Paxinos, 1997). The VO was chosen for depth-
electrode placement because this part of the mouse brain (together with
the nearby medial orbital and cingulate cortex) represents a relatively
cholinesterase-rich region of the mouse cortex (Franklin and Paxinos,
1997) corresponding to the human homologs of ictal focus (mesial and
orbital frontal cortex) as identified by video–electroencephalogram
monitoring, interictal positron emission tomography, and focal hyper-
perfusion on ictal single photon emission computerized tomography
studies in ADNFLE (Hayman et al., 1997). The animals were also
equippedwithmonopolar epidural electrodesmade of insulated stainless
steel wire (0.051 mm in diameter) with insulation removed at the tip,
positioned over the right somatosensory cortex (0.9 mm posterior to
bregma and 2.5mm lateral tomidline) and the left and right visual cortex
(4.5 mm caudal to bregma and 2.5 mm lateral to midline) (Franklin and
Paxinos, 1997). Each electrode was connected to an electrode interface
board (Qube3, Melbourne, Australia), which was attached to the skull
and cemented in place using dental cement. The animals were allowed to
recover, and all recordings were made from animals between 3 and 10
days after surgery. EEG activities were recorded with a computer-based
digital acquisition system (Chart version 5.4.2; ADInstruments, Sydney,
Australia) with concurrent video recording for behavioral analysis
(Quicktime Capture Module version 1.2.2). All animals were placed in a
glass cage and allowed ad libitum access to food and water. EEG signals
were referenced to signals from a ground screw implanted in the bone
over the frontal association cortex. EEG recording from each animal was
monitored for several hours between 9:00 A.M. and 4:00 P.M. immedi-
ately before injection of nicotine. Animals were then given injections of
nicotine (2mg/kg, i.p.) followed by pentylenetetrazole (PTZ) (70mg/kg,
s.c.) to ensure that all electrodes were adequate for recording seizure
activity. After completion of the recording experiments, animals were
given injections of a lethal dose of Nembutal (100 mg/kg, i.p.) and per-
fusedwith 4%paraformaldehyde (PFA). Brains were removed and equil-
ibrated in sucrose, and 50 m sections were cut on a cryostat. Histolog-
ical analysis was performed after neutral red staining to verify the
location of the VO depth-electrode.
Epidural electrodes only were used in electroencephalograms under-
taken on 10th backcrossed C57BL/6 S248F knock-in and WT mice. For
these experiments, monopolar epidural electrodes made of insulated
stainless steel wire (0.051 mm in diameter) with insulation removed at
the tip were positioned over the left and right somatosensory cortex (0.9
mm posterior to bregma and 2.5 mm lateral to midline) and the left and
right visual cortex (4.5 mm caudal to bregma and 2.5 mm lateral to
midline) (Franklin and Paxinos, 1997).
Behavioral studies. All drugs used in this study for intraperitoneal in-
jections were made up in 0.9% saline and were injected in a volume ratio
of 100 l/13 g body weight. For the seizure study, drug-naive male and
female heterozygous and WT mice between 11–17 weeks of age, from
three different genetic backgrounds [mice derived by mating germline-
transmitting chimeras with CD1 congenic EIIa/Cre homozygous mice
(CD1/129Sv),mice derived fromcrossingCD1/129Sv heterozygousmice
once with C57BL/6mice (BL6 N1), andmice backcrossed five times on a
C57BL/6 background (BL6N5)], and4/ knock-outmice and litter-
mate control mice (both of hybrid 129SvJ/C57BL/6 background) (Ross
et al., 2000) were used in these experiments. All experiments were per-
formed between 9:00 A.M. and 1:00 P.M. Each animal received a single
intraperitoneal injection of 2, 6, or 8 mg/kg body weight nicotine imme-
diately before being placed in a glass aquarium, and their seizure-like
behavior was scored using a modified behavioral scale (Franceschini et
al., 2002): 0, no identifiable seizure-like activity as defined by the pres-
ence of tremors, wild running, tonic–clonic seizure activity, or death; 1,
head and/or body oscillatory tremors; 2, wild running; 3, loss of righting
response and clonic seizure; 4, death after a clonic seizure. These behav-
ioral end points were chosen for inclusion in our seizure scale because
they were either correlated with unequivocal cortical EEG spike-and-
wave activity or were noted to give rise to hippocampal correlates of
seizure activity on c-fos-regulated gene expression studies (data not
shown). All experiments were videotaped to allow post hoc evaluation. In
all cases, experimenters were blind to genotype and drug dose. Fifteen
male and 15 female heterozygousmice and the same number ofWTmice
were used for each of the three doses of nicotine used in each of the three
genetic backgrounds tested.
For the mecamylamine experiments, heterozygous BL6 N1 female
mice 14–16 weeks of age were given intraperitoneal injections of either
0.5 mg/kg mecamylamine (n  9) or saline (n  6). Ten minutes later,
mice received 8 mg/kg nicotine intraperitoneally and were placed in a
glass aquarium, and their behavior was monitored and recorded.
For the carbamazepine study, BL6 N1 female heterozygous mice (n
35) were administered carbamazepine intraperitoneally at 0, 40, or 60
mg/kg. Carbamazepine was dissolved in 45% w/v 2-hydroxypropyl--
cyclodextrin. Twenty minutes after drug administration, locomotion
was scored using a simple quadrant entry paradigm. Briefly, the floor of
the glass-walled observation arena (36 20 20 cm)was evenly divided
into six quadrants. The number of quadrants the mouse entered with all
four limbs over a 2 min period was scored by an experimenter who was
blind to drug dose. Immediately after completion of locomotion scoring,
the mouse was administered 1 mg/kg nicotine intraperitoneally and re-
turned to the arena for behavioral scoring. The scoring period lasted 5
min. All experiments were videotaped to allow post hoc analysis. Two
weeks later, animals were randomly assigned to different doses of car-
bamazepine, and the experiment repeated using a nicotine challenge (2
mg/kg, i.p.).
Fos–Tau–LacZ study. Individually housed WT and S248F knock-in
mice heterozygous for the S248F mutation and Fos–Tau–LacZ (FTL)
transgene [BL6 N1 mice (both male and female)] were given intraperi-
toneal injections with saline and 2 or 6 mg/kg nicotine. Two hours after
drug administration, animals were deeply anesthetized using Lethabarb
(0.35mg/g) and perfusedwith 50ml of ice-cold PBS, followed by 50ml of
2% PFA and 0.005% glutaraldehyde. Whole brains were removed and
stored overnight in 30% sucrose in PBS. The following day, 40m coro-
nal sections were cut using a cryostat and collected in cryoprotectant.
Sections were rinsed in PBS and incubated overnight at 37°C in 5 mM
potassium ferricyanide, 5mMMgCl2, and 0.4mg/ml X-gal (Wilson et al.,
2002). The reactionwas stopped by the addition of 0.5%PFA in PBS, and
the sections were washed and mounted in 0.5% gelatin. Sections repre-
sentative of 2.2 mm posterior to bregma (Paxinos and Franklin, 2001)
were identified, and images were obtained using Pictureframe software.
The number of LacZ-positive neurons in the CA1, dentate gyrus, and
pyramidal cell layer of the hippocampus were determined using ImageJ
software.
Intracerebroventricular injections. Female heterozygous CD1/129Sv
and BL6 N1 hybrid genetic background mice were anesthetized with 5%
chloral hydrate in saline and secured in a stereotaxic apparatus, and the
skull was leveled between bregma and lambda. A 23 gauge stainless steel
guide cannula was implanted into the lateral ventricle, 0.5 mm posterior
to bregma, 1 mm lateral of the midline, and 1.2 mm below the surface of
the skull (Franklin and Paxinos, 1997). The cannula was secured to the
skull using dental acrylic and plugged with a stainless steel obturator.
Mice were allowed 1 week to recover from surgery. A prefilled 30 gauge
injector was inserted into the cannula, and the mouse was placed in the
test arena.Oneminute later, 17.5g of nicotine (at a concentration of 3.5
g/l) was administered over 1min and behavior was scored. The injec-
tor remained in position throughout the experiment. Chlorisondamine
is a sympathetic cholinergic ganglion blocker that does not readily cross
the blood–brain barrier (Clarke, 1984). Chlorisondamine (1 mg/kg in
0.2ml) was administered intraperitoneally 30min before intraperitoneal
nicotine (2mg/kg) challenge. Chlorisondamine (25 nmol/mouse in 5l)
was then administered by intracerebroventricular injection 30 min be-
fore nicotine (2 mg/kg, i.p.) to determine whether the dystonic arousal
complex (DAC) was mediated by central nicotinic receptors.
[125I]Epibatidine autoradiography. The procedure was based on a pre-
vious study (Pradhan et al., 2002). Briefly, brain sections frommice were
thawed to room temperature and preincubated for 10 min at room tem-
perature in buffer containing (inmM) 50 Tris, 120 NaCl, 5 KCl, 1MgCl2,
and 2.5 CaCl2, pH 7.0. The slides were then incubated for 2 h at room
temperature in buffer with 15 pM [125I]epibatidine (2200 Ci/mmol).
Nonspecific binding was defined by the addition of 300 M nicotine
bitartrate. Sections were then rinsed in ice-cold buffer (twice for 5 min)
and distilled water (2 s). Dried sections were apposed to x-ray film (X-
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Omat AR; Kodak, Rochester, NY) together with [ 14C] standards for 12 h
before developing. The developed films were subsequently quantified
using the Scion (Frederick, MD) Image system (PC version 1.4 of NIH
Image), by comparing the optical densities of autoradiographic images
with those of corresponding standard microscales. After autoradio-
graphic films were developed, the brain slices were stained with 0.1%
thionin, cleared, and coverslipped. Mouse brain nuclei were subse-
quently defined with reference to amouse stereotaxic atlas (Franklin and
Paxinos, 1997). The density of binding to individual brain nuclei is ex-
pressed as dpm/mm2. In every experimental condition, total bindingwas
measured from four consecutive sections per region and nonspecific
binding from two sections per region from each individual mouse for
each region analyzed.Unless indicated otherwise, data are reported as the
mean  SEM. The statistical program SigmaStat (Jandel Scientific, San
Rafael, CA) was used throughout. One-way ANOVA followed by the
Dunnett’s test or a Kruskal–Wallis ANOVA by ranks followed by the
Dunn’s test was performed for the comparison of radioligand binding
parameters between heterozygous or homozygous mice and WT coun-
terparts. A significance level of p 0.05 was used throughout.
[125I]Epibatidine binding to membrane fragments. A previously de-
scribed method (Whiteaker et al., 2000b) was used to prepare mem-
branes from four brain regions: cortex, hippocampus, striatum, and thal-
amus from three genotypes (wild type, heterozygous, and homozygous)
of S248F knock-in mice. Saturation binding experiments were per-
formed as described previously (Whiteaker et al., 2000b). In separate
experiments, inhibition of [ 125I]epibatidine binding was determined us-
ing 200 pM [125I]epibatidine with 0, 50, and 150 nM cytisine. Data were
calculated using a two-site inhibition model.
Synaptosome preparation. Mice were killed by cervical dislocation,
brains were removed and placed on an ice-cold platform, and cortex,
hippocampus, striatum, and thalamus were dissected. Each region was
individually homogenized by hand in ice-cold sucrose (0.32 M) buffered
to pH 7.5 with HEPES (5 mM) using a glass-Teflon tissue grinder. The
homogenates were divided into appropriate aliquots to enable assaying
for several functions from each preparation and centrifuged at 20,000
g for 20 min. The supernatants were removed, and the P1 pellets were
resuspended in the appropriate buffer for uptake of radioactive tracer.
Uptake of radioactive tracers. Previously described methods were used
for 86Rb uptake (Marks et al., 1999), for [ 3H]GABA uptake (Lu et al.,
1998), and for tritiated dopamine ([ 3H]DA) uptake (Salminen et al.,
2004). All synaptosomes were treated with diisopropyl fluorophosphate
(10 M) during the last 5 min of the uptake procedure to inactivate
acetylcholinesterase.
Neurotransmitter release and 86Rb efflux assays.After uptake of radio-
active neurotransmitter tracer, synaptosomeswere aliquotted onto filters
on a perfusion apparatus and perfused for 10 min with buffer (128 mM
NaCl, 2.4 mM KCl, 3.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25
mM HEPES, pH 7.5, 10 mM glucose, 0.1% bovine serum albumin, and 1
M atropine) containing the relevant reuptake inhibitor (100 nM NNC-
711 for GABA or 1 M nomifensine for DA). ACh solutions were made
fresh daily. For experiments using-conotoxinMII (CtxMII) to inhibit
the6*-nAChR, synaptosomes were exposed toCtxMII (50 nM) for the
last 5 min of the 10 min buffer perfusion and immediately preceding the
exposure to ACh. The kinetics of recovery from inhibition byCtxMII is
sufficiently slow that this inhibitor was not includedwith ACh (Salminen
et al., 2004). In experiments with mecamylamine, the indicated concen-
tration was added to the CtxMII-containing buffer, and synaptosomes
were perfused for 5minwith both antagonists before exposure to agonist
with the same concentration ofmecamylamine. For [ 3H]GABA release, a
16 s exposure to ACh or K was used; for [ 3H]DA, the ACh or K
exposure was for 20 s. For both assays, perfusion speed was 0.7 ml/min,
and 10 s fractions were collected into 96-well plates using a Gilson
(Middleton,WI) FC204 fraction collector. Optiphase “Super-Mix” scin-
tillation mixture was added, and radioactivity was determined using a
1450 MicroBeta Trilux scintillation counter (instrument and mixture
from PerkinElmer–Wallac, Turku, Finland). Instrument efficiency was
40%.
86Rb efflux was determined by perfusion of synaptosomes with
buffer (135mMNaCl, 5mMCsCl, 1.5mMKCl, 2mMCaCl2, 1mMMgSO4,
25 mM HEPES hemisodium, 20 mM glucose, 50 nM tetrodotoxin, 1 M
atropine, and 0.1%bovine serum albumin, pH 7.5) at 2.5ml/min (Marks
et al., 1999). Efflux was monitored continuously for 3 min per sample by
pumping effluent through a Cherenkov cell in a -RAM Radioactivity
HPLC Detector (IN/US Systems, Tampa, FL). A 5 s exposure to agonist
was used. Formecamylamine treatment, the indicated concentrationwas
added to the buffer and also included with agonist.
Xenopus oocyte electrophysiology. Rat WT and mutant 42-nAChRs
were expressed in Xenopus oocytes as described previously (Rodrigues-
Pinguet et al., 2003). Surgical excision of the oocytes from Xenopus was
performed according to NIH and California Institute of Technology
guidelines. Isolated oocytes were injected with 10 ng of either WT 4 or
4 (S252F, which aligns withmouse S248F) and 15 ng of 2 cRNA. After
injection, the oocytes were incubated in amodified Barth’s solution con-
taining 96 mM NaCl, 5 mM HEPES, 2.5 mM sodium pyruvate, 2 mM KCl,
1.8mMCaCl2, 1mMMgCl2, 2.5g/ml gentamicin (Sigma), and 5%horse
serum, pH 7.4 (Irvine Scientific, Santa Ana, CA) for 3–6 d before record-
ing. To measure the ACh responses of the expressed receptors, the oo-
cytes were voltage clamped at 50 mV with 3 M KCl-filled microelec-
trodes; continually superfused with a nominally Ca2-free saline
containing (mM) 98 NaCl, 1 MgCl2, and 5 HEPES, pH 7.4, at 20–23°C;
and bath applied with 2 M ACh. In the mecamylamine experiments,
mecamylamine was applied 2 min before, during, and for 2 min after the
second ACh application. The responses were filtered at 20 Hz and digi-
tized at 100 Hz using a PC equipped with pCLAMP 9.2 software (Molec-
ular Devices). One-way ANOVA and the Dunnett’s test were used to test
for significant differences between the peak responses.
Results
S248F knock-in mice express the mutant allele
A targeting construct used to generate the 4 L9S mouse (La-
barca et al., 2001) was modified to correct the original L9Smu-
tation and introduce the S248Fmutation at the 6 position in the
putativeM2 region of the4-nAChR subunit gene. The targeting
vector contained the exon 5 portion of the 4-nAChR subunit
carrying the S248F (TCG3TTT) mutation. The linearized con-
struct (Fig. 1A) was electroporated into theW9.5 ES cell line, and
recombinant clones were identified by Southern blotting (Fig.
1B, lanes 3 and 4). High-percentage agouti coat color germline-
transmitting chimeric mice were mated with CD1 background
adenovirus EIIa/Cre homozygous transgenic mice (Lakso et al.,
1996) to splice out the neomycin phosphotransferase selection
cassette, thereby ensuring full expression of the mutated allele in
heterozygous mice (Fig. 1C). This breeding strategy ensured that
heterozygous and agouti WT control mice had an identical ge-
netic background (i.e., 50% 129/Sv and 50% CD1, and both had
a single copy of the EIIa/Cre transgene). Home-cage behavior,
weight (data not shown), and fertility were normal in both het-
erozygous and homozygous mice. Sequencing of whole-brain-
derived cDNA amplicons confirmed the presence of the S248F
mutation at the mRNA level (Fig. 1D).
The S248F knock-in mutation has minor effects on receptor
binding properties
Quantitative ligand autoradiography with [125I]epibatidine [a li-
gand for42*-nAChRs (Gerzanich et al., 1995;Davila-Garcia et
al., 1997)], demonstrated similar binding levels in most brain
regions examined in male WT and heterozygous mice. Homozy-
gous mice showed higher than WT binding in a few regions:
fasciculus retroflexus, posterior hypothalamus, and dorsolateral
geniculate (Fig. 2A).
In a separate experiment, total [ 125I]epibatidine binding (200
pM) in membrane preparations from four brain regions was as-
sessed (Fig. 2C). No significant differenceswere detected between
genotypes. To further assess nAChR density, saturation binding
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of [125I]epibatidine was performed in
membrane preparations from four re-
gions of WT, heterozygous, and ho-
mozygous S248F mice. In three regions
[cortex (Fig. 2B), hippocampus, and
striatum (data not shown)], there were
no differences between genotypes. A
small decrease was seen in both het-
erozygous and homozygous mice com-
pared with wild type in thalamic mem-
branes (Fig. 2B, bottom).
To isolate different populations of
nAChR subtypes, cytisine-sensitive and
cytisine-resistant [125I]epibatidine bind-
ing were determined in membrane prepa-
rations from four regions (Fig. 2D,E).
Cytisine-sensitive sites represent mainly
the 42*-nAChRs, whereas cytisine-
resistant subtypes include amixed popula-
tion of nAChRs containing 3, 6, 2, 3,
and 4 subunits (Whiteaker et al., 2000b;
Marks et al., 2006). No significant differ-
ences were observed between genotypes
for either cytisine-sensitive or cytisine-
resistant [125I]epibatidine binding. Over-
all, the binding data indicate that the
S248Fmutation confers little change in re-
ceptor numbers in most regions, although
there are rather small increases or de-
creases in a few regions.
S248F knock-in mice display altered
synaptosomal nAChRs function
The function of nAChRs was assessed in synaptosomal prepara-
tions using several assays. ACh-stimulated [3H]DA release from
striatal synaptosomes (Fig. 3A), 86Rb efflux from thalamic syn-
aptosomes (Fig. 3B), and [3H]GABA release from hippocampal
synaptosomes (Fig. 3C) were measured fromWT, heterozygous,
and homozygous mice. Dopamine release is mediated by two
classes of nAChRs (Salminen et al., 2004): those resistant to inhi-
bition by CtxMII (Fig. 3A, top), which are 42*-nAChRs, and
those sensitive to CtxMII inhibition (Fig. 3A, bottom), which
are 62*-nAChR subtypes. The results show that dopamine
releasemediated by theCtxMII-resistant subtypes is affected by
the S248F mutation, whereas release mediated by the CtxMII-
sensitive subtypes does not differ with genotype. 86Rb efflux is
mediated by two populations of nAChRs, a low- and a high-
affinity form, both thought to be 42* subtypes (Marks et al.,
2007). In addition, [3H]GABA release appears to be mediated by
42*-nAChRs (Whiteaker et al., 2000a).
The patterns of change are similar for all three functions
mediated by 42*-nAChRs, including CtxMII-resistant
dopamine release, high- and low-affinity 86Rb efflux, and
[ 3H]GABA release (Fig. 3A–C). At low agonist concentra-
tions, the S248F knock-in mice have nearly normal nAChR
function, and at high agonist concentrations, the S248F mice
have decreased responses. Figure 3, E and F, present dose–
response parameters abstracted for those measures mediated
by the 42* subtypes of nAChRs functions. Figure 3E shows
that the S248F mutation results in significantly decreased
42* maximal function. This mutation results in a signifi-
cantly higher-affinity nAChR as seen in the shifts in EC50 val-
ues for ACh (Fig. 3F ) for both the heterozygous and homozy-
gous S248F knock-in mice. The function of the CtxMII-
sensitive subtypes, assessed both by maximal activity and by
EC50 value, are unchanged by this mutation. The loss of func-
tion seen with high agonist concentrations is similar to what
has been reported previously (Kuryatov et al., 1997, 2005) and
was postulated to result from a change in stoichiometry of
subunit assembly (Kuryatov et al., 2005).
S248F knock-in mice do not have spontaneous seizures
In an initial set of experiments, EEG recordings with video mon-
itoring of mutant mice [heterozygous (n  8) and homozygous
(n 5)] and WT littermates (n 3) undertaken over a 12–16 h
overnight period and for periods of 4–6 h during the daylight
hours were normal. In particular, mutant mice displayed no be-
havior suggestive of spontaneous seizures and no electrographic
abnormalities (data not shown). The same EEG paradigm has
been shown to detect behavior and electrographic signs of PTZ-
induced seizures (McColl et al., 2003) and spontaneous seizures
in another mutant line (Gantois et al., 2007). Initial studies on
S248F mice were performed on mice of two different genetic
backgrounds including the CD1/129Sv (n 5 heterozygous, n
5 homozygous, and n 3WT littermates) and CD1/129Sv back-
crossed four generations (N4) into the C57BL/6 strain (called
BL6 N4; n  3 heterozygous). In a second set of experiments,
epidural electroencephalograms (using the second epidural re-
cording paradigm described above) with video monitoring were
recorded for 10 h during daylight hours from a total of 11 mice
backcrossed 10 generations on a C57BL/6 genetic background
(BL6 N10; two WT and eight heterozygous mice and one ho-
Figure 1. Generation of S248F ADNFLE mouse. A, Gene-targeting strategy. The targeting construct contained exon 5 of the
mouse4-nAChR subunit genewith the S248Fmutation and a LoxP-flanked neomycin phosphotransferase cassette located 163
bp downstream of this exon. Homologous recombination results in the insertion of a novel EcoRI site. A flanking probe comple-
mentary to DNA downstreamof a BamHI sitewas used to confirm correct targeting of a BamHI–EcoRI genomic digestwhere aWT
allele generates a9.7 kbBamHI–BamHIband,whereas a targetedallele gives a7.7 kbBamHI–EcoRIband.DTA,Diphtheria toxin-A
chain.B, Random insert ES cell clones containedonly theWT9.7kb fragments (lanes1, 2),whereas the correctly targetedES clones
contained theWT 9.7 kb and the targeted 7.7 kb bands (lanes 3, 4). C, High-percentage chimeras containing the S248Fmutation
with a LoxP-flanked neomycin gene were mated with homozygous adenovirus EIIa/Cre recombinase mice to splice out the
neomycin cassette and allow full expression of the targeted4-nAChR allele. D, The presence of the mutation was confirmed by
sequencing analysis of amplicons synthesized from total brain cDNA. WT mice showed the original serine codon (TCG), whereas
heterozygous and homozygousmice displayed the introduced phenylalanine codon (TTT) in a gene dose-dependentmanner. The
result of sequencing of WT, homozygous (HT), and homozygous (HM) brain-derived amplicons.
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mozygous mouse). Electrographic spike-and-slow wave seizures
were never seen.
In summary, a total of 22 S248F knock-in mice were moni-
tored with epidural electrodes, and no epileptiform spike-and-
wave events were detected. Spontaneous behavioral seizures were
never seen in this cohort or in a separate cohort of 40 heterozy-
gous and 21 homozygous mice on a BL6 N10 background
observed during routine laboratory handling. Furthermore,
spontaneousmotor seizures were never observed during the day-
to-day handling of 160 homozygous and 	1000 heterozygous
mice observed over a 2 year period by staff trained in the recog-
nition of mouse seizures. In conclusion, S248F mutant mice do
not appear to have behavioral or electrographic spontaneous
seizures.
Figure 2. [ 125I]Epibatidine binding in S248F knock-in mice. A, Quantitative autora-
diography of [ 125I]epibatidine binding to mouse brain. WT (n 10), heterozygous (HT;
n 9), and homozygous (HM; n 9) mice were assessed, and binding data were plotted
as percentage of wild type (mean SEM) for comparative purposes. *p 0.05 vs WT
mice; #p 0.05 vs heterozygous mice. B, [ 125I]Epibatidine saturation binding to mem-
branes. Binding data (means SEM) are shown (n 4 for each genotype) using cortex
and thalamusmembranes and eight concentrations of [ 125I]epibatidine (4 –350 pM). Data
shown are specific binding (total binding minus nonspecific binding determined by the
addition of 100M cytisine). Hippocampus and striatummembrane binding had patterns
similar to cortex (data not shown). Binding was reduced in the thalamus of HT and HM
S248F mice. *p 0.05, significant differences from wild type. C, Total specific binding of
[ 125I]epibatidine to membranes prepared from four brain regions. Each bar represents
specific binding (mean SEM) from five mice of each genotype, using 200 pM [ 125I]epi-
batidine. No significant differences were found. D, E, Cytisine-sensitive and cytisine-
resistant [ 125I]epibatidine binding. Total specific binding (shown in C) as well as binding
in the presence of cytisine (50 and 150 nM) were measured, and the data were fitted to a
two-site model to determine the amounts of binding sensitive and resistant to cytisine
(Whiteaker et al., 2000b). EPI, [ 125I]Epibatidine; CPu, caudate putamen; CTX, cortex; fr,
fasciculus retroflexus; MHb,medial habenular; PH, posterior hypothalamus; TH, thalamus;
Tu, tubercle; SNc, substantia nigra pars compacta; DLG, dorsolateral geniculus;
VTA, ventral tegmental area; IPn, interpeduncular nucleus; SC, superior colliculus; ST,
striatum.
Figure 3. Synaptosomal function in S248F knock-in mice. A, [ 3H]DA release from striatal
synaptosomes. Release was stimulated by a 20 s exposure to the indicated concentrations of
ACh. Data shown are mean SEM for five mice of each genotype. In the top graph, synapto-
somes were exposed to CtxMII (50 nM) for 5 min before ACh exposure to determine release
mediated by nAChR subtypes resistant to that treatment. In the bottom graph, the amount of
release resistant toCtxMII was subtracted from release by AChwithout exposure toCtxMII.
This difference represents releasemediated by nAChR subtypes sensitive toCtxMII. Release is
in units (counts per minute normalized to baseline counts per minute). B, 86Rb efflux from
thalamic synaptosomes. Efflux of 86Rbwas stimulated by a 5 s exposure to ACh. Data shown
aremeans SEM for fivemice of eachgenotype. Efflux fromcortical synaptosomes showed the
same pattern (data not shown). C, [ 3H]GABA release from hippocampal synaptosomes.
[ 3H]GABA was stimulated by a 16 s exposure to the indicated concentrations of ACh. Data
shown are means SEM for five mice of each genotype. Release from cortical synaptosomes
showed the same pattern (data not shown).D, Comparison of neurotransmitter release stimu-
lated by 20mM K. Data shown are means SEM for five mice of each genotype. E, Compar-
ison of maximal effect of ACh for various measures of synaptosomal function. Data were com-
paredbyone-wayANOVAwithDuncan’spost hoc test. Significant differences fromwild type are
shown (*p 0.05) . F, Comparison of EC50 values for ACh for various assays of synaptosomal
function. Data were compared by one-way ANOVA with Duncan’s post hoc test. Significant
differences from wild type are shown (*p 0.05). HT, Heterozygous; HM, homozygous; TH,
thalamus; HP, hippocampus; ST, striatum.
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S248F knock-in mice display the novel
nicotine-induced DAC
When we injected heterozygous mice of
the CD1/129Sv background with 2 mg/kg
nicotine, we noted three distinct stereo-
typic behaviors collectively termed the
DAC (see S248F DAC1 video, available at
www.jneurosci.org as supplemental mate-
rial). The first component, termed sac-
cadic behavior, involves aroused, jerky,
exploration-like darting of the head in
random directions accompanied by
whole-body movements in the same di-
rection. This continues for 9  1 s
(mean  SEM; n  24) and is then fol-
lowed by the second stereotypical phase,
termed the forelimb dystonia phase. In
this phase, the trunk is extended forward,
as if themouse is stretching: natural, upright supported posture is
lost, and the animal becomes prone (Fig. 4A). In extreme cases,
extended and supinated forelimbs cross themidline in a dystonic
posture (Fig. 4B). The arms supinate and forelimbs flex at the
elbows, wrists, and digits, so that eventually the paws clasp to-
gether below the chin (Fig. 4B). Although the second phase oc-
curs in males and females, forelimb crossing and digital clasping
is more common and prominent in female mice. In the third
component of the DAC, the tail occupies the Straub configura-
tion, bent 180° from its natural position (Fig. 4A). The Straub tail
begins simultaneously with trunk extension and forelimb dysto-
nia. Occasionally, prominent flexion–extension head and body
jerking is seen as the tail collapses. The three phases of the DAC
last 36 3 s (mean SEM), atwhich normal upright posture and
natural exploratory behavior is re-established. Balance is pre-
served during theDAC. This can be appreciated by examining the
S248F DAC2 video (available at www.jneurosci.org as supple-
mental material) in which the mouse manages to remain upright
and not fall off the platformdespite its hindquarters hanging over
the edge and a hand-clap noise startle. BothDACvideos provided
showdigital spreading, which also accompanies the forelimb dys-
tonic posturing. Please note that upper-limb dystonic posturing
with digital spreading was reported by Scheffer et al. (1995).
A systemof scoring the Straub tail and forelimbdystonia com-
ponents of the DAC was developed to quantify the magnitude of
the DAC response. Mice were scored from 0 to 4 for Straub tail
depending on the angle that the long axis of the tail makes with
the horizontal plane (0, no Straub tail observed; 1, a rigid tail
between 0 and 45°; 2, tail raised between 45 and 90°; 3, tail raised
between 90 and 135°; 4, tail raised beyond 135°) and from 0 to 3
for the degree of forelimb dystonia [0, no dystonia observed; 1,
isolated forward stretching of the forelimbs; 2, stretching plus
supination (rotation of the forelimbs along a long axis in a direc-
tion away from the midline); 3, midline crossing or folding of
stretched and supinated forelimbs].
The DAC is a centrally mediated phenotype modified by
gender, genetic background, and S248F expression levels
The DAC scoring system was applied to quantify the response of
heterozygous mice (n  23 males and n  23 females on the
129/CD1 background) that received injections of 2 mg/kg nico-
tine intraperitoneally. One hundred percent of female heterozy-
gous mice displayed all three component behaviors of the DAC
(saccadic behavior, Straub tail score of 3, and forelimb dysto-
nia) compared with only 75% of heterozygous males (z test, p
0.033). Compared with males, female heterozygous mice
achieved significantly higher scores for Straub tail (females, 3.7
0.1; males, 3.0 0.2; Mann–Whitney rank sum test, p 0.004)
and forelimb dystonia (females, 2.2  0.1; males, 1.5  0.1;
Mann–Whitney rank sum test, p 0.002). Saccadic behavior and
forelimb dystonia was never seen inWTCD1/129Sv background
mice (n 23 females and n 24males), butWTmice did display
a low-grade Straub tail. A Straub tail was seen in 96% of WT
females compared with only 64% of males (z test, p  0.019).
Female WT mice scored significantly higher than males for
Straub tail (Mann–Whitney rank sum test, p  0.001). Overall,
the WT Straub tail response was less than for the Straub tail
scored as part of theDAC response in heterozygousmice (average
score: maleWTmice, 0.8 0.1 vsmale heterozygousmice, 3.0
1.8; p 0.001; femaleWTmice, 1.6 1.2 vs female heterozygous
mice, 3.7  0.1; Mann–Whitney rank sum test, p  0.001).
Hence, a Straub tail score of3 was considered the threshold for
defining aDAC-like Straub tail. The same experimentwas under-
taken in heterozygous mice on a (BL6 N1) background (n  36
males and n  36 females) given injections of 2 mg/kg nicotine
intraperitoneally. Ninety-four percent of female heterozygous
mice displayed all three component behaviors of the DAC
(saccadic behavior, Straub tail of 3, and forelimb dystonia)
compared with only 89% of heterozygous males. Female het-
erozygous mice achieved significantly higher scores for fore-
limb dystonia (females, 2.5  0.1; males, 1.5  0.1; Mann–
Whitney rank sum test, p 0.01) on this background although
there was no difference observed in scores for Straub tail in
this background. These data suggest that the DAC has a greater
penetrance in females. For this reason, experiments under-
taken to investigate the DAC were mostly undertaken on fe-
male mice.
The latency to the DAC was surprisingly brief, 24  3 s
(mean  SEM), raising the possibility that it was triggered by
activation of peripheral rather than central nAChR receptors.
The DAC could be reproduced by direct intracerebroventricular
injection of nicotine (17.5 g; n  8). Moreover, the DAC was
completely abolished by previous intracerebroventricular (25
nmol/mouse in 5 l; n  7), but not peripheral (1 mg/kg in 0.2
ml; n 2), administration of chlorisondamine, a nicotinic recep-
tor antagonist that does not readily cross the blood–brain barrier
(Clarke, 1984).
Although the DAC was consistently observed in mice with
various genetic backgrounds including CD1/129Sv and BL6
N1, the phenotype was subtly modified in BL6 N1 mice and
Figure 4. DAC. A, A heterozygous mutant mouse on a CD1/129Sv genetic background that received an injection of 2 mg/kg
nicotine displays the 180° Straub tail (black arrow). B, An example of marked forelimb dystonia, part of the DAC, in a S248F
knock-inmouse that received an injection of 2mg/kg nicotine showsmidline crossing of the forelimbs culminating in the clasping
of digits (black arrow). C, AWTmouse that received an injection of 2mg/kg nicotine displays no behaviors attributable to the DAC.
An incomplete Straub tail, as exemplified by thismouse, is rarely beyond90° to the horizontal plane, and themouse showsnormal
upright forelimb posturing.
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substantially modified in mutant mice backcrossed five gen-
erations into the C57BL/6 background (BL6 N5). BL6 N1mice
typically continued to roam after onset of the DAC. In BL6 N5
background heterozygous mutant mice, the Straub tail was
still present to the same degree, but the forelimbs were rarely
totally out-stretched, supinated, or crossed with associated
digital clasping; rather, mice repeatedly dragged their fore-
limbs under their body and across the midline as they walked.
In the BL6 N5 background, saccadic behavior was markedly
reduced [percentage of mice displaying saccadic behavior after
2 mg/kg nicotine: CD1/129Sv, 87% (n  30); BL6 N1, 100%
(n 30); BL6 N5, 33% (n 30); BL6 N5mice are significantly
different from other groups; Kruskal–Wallis test followed by
post hoc Tukey’s test, p  0.05], but mice moved forward in
jerk-like steps, and forelimb dystonia was subtle and manifest
as forelimb supination with clenched fists and rhythmic fore-
limb retraction and extension during accelerated jerky ambu-
lation. The accentuated Straub tail response was maintained in
this genetic background. A 2 mg/kg dose of nicotine often
induced body tremors in the BL6 N5 mice, although this also
occurred in mice with WT 4 receptors (Table 1). The atten-
uated DAC in heterozygous BL6 N5 mice (loss of saccadic
behavior and modification of dystonia) seemed to result from
response competition related to locomotor hyperactivity and
body tremors.
Neomycin cassette intact CD1/129Sv background het-
erozygous mice were also available for testing. These mice
were generated from matings between neomycin intact pure
129Sv background heterozygous knock-in mice and homozy-
gous adenovirus EIIa/Cre mice in which recombination failed
entirely [a phenomenon seen previously with this line of Cre
activator mice (Drago et al., 1998)]. In this experiment, mice
were tested only once. Twenty-eight of 29 mice examined dis-
played saccadic behavior and/or Straub tail but not forelimb
dystonia when given 2 mg/kg nicotine. One of 29 mice dis-
played forelimb dystonia with this dose of nicotine. This com-
pares with 18 of 30 neomycin cassette-deleted CD1/129Sv
mice that displayed forelimb dystonia in this study (z test, p
0.001). At higher doses of nicotine, the forelimb dystonia re-
appeared (6 mg/kg, 12 of 29 mice; 8 mg/kg 11 of 30 mice),
although the degree of dystonia was less (average dystonia
score at 8 mg/kg nicotine: CD1/129Sv, 2.2  0.2; neomycin
intact CD1/129Sv, 0.7  0.2; Mann–Whitney rank sum test,
p 0.001). The observation that gene expression is reduced by
the presence of the neomycin cassette at this gene locus (Fonck
et al., 2003) suggests that the most ephemeral component of
the DAC is forelimb dystonia and that the complete phenotype
requires full expression of at least one mutant allele.
The DAC was not seen in WT mice of several genetic back-
grounds (CD1/129Sv, BL6 N1, 129SvJ/C57BL/6, BL6 N5) at a
range of nicotine doses (2, 4, and 8 mg/kg; n  120 for each
nicotine dose amounting to a total of 360 WT mice examined).
Other than in the BL6 N5 background, locomotor activity was
reduced in WT mice given low doses of nicotine (2 mg/kg). The
mice remained upright but were immobile and sat in a resting
position (Fig. 4C). The tail elevation displayed byWTmice rarely
exceeded 90° above the horizontal plane (Fig. 4C), and the onset
was 104 12.8 s (mean SEM; n 90) after nicotine injection.
This incomplete Straub tail in WT mice was usually observed
with convulsive doses of nicotine (6–10mg/kg) and was typically
followed by a tonic–clonic seizure.
Table 1. Nicotine-induced seizure dose responses
Background Genotype Nicotine Score 0 Score 1 Score 2 Score 3 Score 4
Score 3
 4
CD1/129Sv WT 2 83.33 (25) 13.33 (4) 3.33 (1) 0.00 (0) 0.00 (0) 0 (0)
6 3.33 (1) 16.67 (5) 33.33 (10) 43.33 (13) 3.33 (1) 47 (14)
8 0.00 (0) 3.33 (1) 13.33 (4) 50.00 (15) 33.33 (10) 83 (25)
Heterozygous 2 96.67 (29) 0.00 (0) 3.33 (1) 0.00 (0) 0.00 (0) 0 (0)
6 16.67 (5) 3.33 (1) 33.33 (10) 40.00 (12) 6.67 (2) 47 (14)
8 3.33 (1) 6.67 (2) 30.00 (9) 46.67 (14) 13.33 (4) 60 (18)
BL6 N1 WT 2 83.33 (25) 16.67 (5) 0.00 (0) 0.00 (0) 0.00 (0) 0 (0)
6 0.00 (0) 6.67 (2) 33.33 (10) 40.00 (12) 20.00 (6) 60 (18)
8 6.67 (2) 6.67 (2) 13.33 (4) 20.00 (6) 53.33 (16) 73 (22)
Heterozygous 2 96.67 (29) 3.33 (1) 0.00 (0) 0.00 (0) 0.00 (0) 0 (0)
6 20.00 (6) 13.33 (4) 23.33 (7) 16.67 (5) 26.67 (8) 43 (13)
8 10.00 (3) 0.00 (0) 16.67 (5) 30.00 (9) 43.33 (13) 73 (22)
BL6 N5 WT 2 53.33 (16) 40.00 (12) 0.00 (0) 6.67 (2) 0.00 (0) 6 (20)
6 0.00 (0) 0.00 (0) 0.00 (0) 46.67 (14) 53.33 (16) 100 (30)
8 0.00 (0) 0.00 (0) 0.00 (0) 36.67 (11) 63.33 (19) 100 (30)
Heterozygous 2 66.67 (20) 26.67 (8) 3.33 (1) 3.33 (1) 0.00 (0) 3 (1)
6 10.00 (3) 13.33 (4) 0.00 (0) 56.67 (17) 20.00 (6) 76 (23)
8 0.00 (0) 0.00 (0) 0.00 (0) 53.33 (16) 46.67 (14) 100 (30)
129SvJ/C57/B6 WT 2 93.33 (28) 6.67 (2) 0.00 (0) 0.00 (0) 0.00 (0) 0 (0)
6 20.00 (6) 40.00 (12) 10.00 (3) 23.33 (7) 6.67 (2) 30 (9)
8 6.67 (2) 16.67 (5) 3.33 (1) 40.00 (12) 33.33 (10) 73 (22)
Homozygous 2 96.67 (29) 3.33 (1) 0.00 (0) 0.00 (0) 0.00 (0) 0 (0)
6 23.33 (7) 6.67 (2) 16.67 (5) 33.33 (10) 20.00 (6) 53 (16)
8 13.33 (4) 0.00 (0) 3.33 (1) 40.00 (12) 43.33 (13) 83 (25)
A nicotine seizure dose–response relationship was determined for WT and heterozygous mice in several genetic backgrounds (CD1/129Sv, BL6 N1, and BL6 N5). Mice were scored for body tremors (score 1), wild running (score
2), clonic seizures (score 3), and death associated with clonic seizures (score 4). Thirty mice were used for each dose of nicotine tested for each genotype and genetic background. The highest score achieved was recorded for
each mouse. The data represent the percentage of mice obtaining a specific score and the number of 30 (in parentheses) for each test condition. The seizure score was analyzed using ordinal logistic regression as described.
After testing for interactions, a main-effects model was fitted. This showed that the main or average effect of genotype was highly statistically significant (p 0.001); WT mice had a worse seizure profile than heterozygous
mice in all genetic backgrounds. The effect of nicotine dose was also statistically significant, with higher doses leading to worse outcomes (p 0.001). There was also a statistically significant difference of background overall
(p 0.001), with CD1/129Sv being the least affected and C57B6 N5 being the most severely affected. In contrast, there was no significant difference between the nicotine seizure profile of homozygous 4 knock-out and
littermate control WT mice.
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The DAC is not associated with epileptiform changes on
epidural or depth-electrode electroencephalogram or with
changes in hippocampal c-fos-regulated gene expression
Epidural electroencephalograms recorded in mice with a CD1/
129Sv and BL6 N4 genetic background during the DAC were
normal (Fig. 5A), in contrast to tonic–clonic seizure events at
high nicotine doses that showed prominent paroxysmal ictal ac-
tivity (Fig. 5B). Mutant mice given injections of convulsive doses
of nicotine (6–10 mg/kg) showed, in sequence, the DAC associ-
ated with a normal electroencephalogram followed by a clonic
seizure associated temporally with classic ictal electrographic
spike-and-wave activity. The early onset low-dose nicotine-
induced behavioral seizures previously reported in adult L9A
mice (Fonck et al., 2005) were described in both heterozygous
and homozygous mice. They were always preceded by a Straub
tail, followed by loss of the righting response and ending with
forelimb clonus. These behavioral seizures were not associated
with spike-and-wave EEG changes. When adult L9A mice
(Fonck et al., 2005) were given injections of high doses of nico-
tine, two behaviors were observed: early-onset behavioral sei-
zures as described above and late-onset classic tonic–clonic sei-
zures. Only the latter were associated with epileptiform EEG
changes. There are therefore clear parallels between what has
been previously reported (Fonck et al., 2005) and the EEG-
negative DAC described in our study.
In additional experiments, depth-electrode and epidural
long-termEEG recordingwith videomonitoringwas undertaken
on eight female CD1/129Sv background adult heterozygous
S248F mice after injection of nicotine (2 mg/kg, i.p.) or PTZ
(50–70 mg/kg, s.c.). No spontaneous electrographic seizures
were observed during a minimum of 10 h of cumulative baseline
daytime recording undertaken before nicotine injections in any
of the eight heterozygous mice. After injection of nicotine, a typ-
ical DAC was observed in all mice. During these events, no ab-
normal EEG events or changes in neuronal activity in the VO
were observed (Fig. 5C). These experiments were then termi-
nated by a positive control manipulation, injection of a convul-
sive dose of PTZ (Fig. 5D,E). PTZ typically elicited brief myo-
clonic jerks, progressing to clonic seizures, and a hindlimb
extension tonic maximal seizure. There was a corresponding in-
crease in neuronal activity in the depth-electrode and polyspikes
in the surface EEG recordings during PTZ-induced myoclonic
jerks and clonic seizure (Fig. 5D,E).
Mutant S248F knock-in mice on a BL6 N10 genetic back-
ground were also examined using a standard epidural recording
paradigm (the second epidural paradigm described in Materials
andMethods). TwoWT, one homozygous, and six heterozygous
mice (all on a BL6N10 genetic background)were given injections
of 2 mg/kg nicotine and monitored by simultaneous video and
EEG recording. All knock-in S248F BL6N10mice had amodified
DAC as seen typically in this genetic background characterized by
side-to-side head movements, jerky ambulation and paroxysmal
forelimb extension/supination, and a Straub tail response. Epi-
leptiform activity was not observed during EEG monitoring of
the DAC.
In summary, we monitored a total of 30 S248F knock-in mice
for at least 10 h each and did not detect electrographic seizures.
Twenty-eight of these were also given injections of nicotine, and
all showed the DAC, but in the absence of signature epileptiform
changes on the electroencephalogram. All nicotine injections
were undertaken between 9:00 A.M. and 6:00 P.M.
To determine the parts of the brain activated during the DAC,
the S248F mutants were bred with c-fos promoter-driven Tau–
LacZ reporter mice (Wilson et al., 2002). Mice were given injec-
tions of a DAC-inducing dose of nicotine (2 mg/kg) or of a con-
vulsive dose of nicotine (6 mg/kg). A total of 33 mice were used
for this study. Background brain LacZ levels were determined by
examining six saline-injected heterozygous S248F/FTL mice and
six saline-injected FTL single transgenic mice. Four mice het-
erozygous for both the S248F mutation and the FTL transgene
and six FTL single transgenic mice were given injections of 2
mg/kg nicotine. Six mice heterozygous for both the S248F muta-
tion and the FTL transgene and five FTL single positivemice were
Figure 5. Electroencephalograms. A, Traces from epidural electroencephalograms during
nicotine-induced DAC do not differ from normal background electroencephalograms. Ai shows
a trace from a male WT mouse (CD1/129Sv genetic background) 21 weeks of age before and
after 2mg/kgnicotine injection. Theopenarrowhead indicates the29 s timepoint after nicotine
injection. Aii shows a trace from a male heterozygous (HT) mouse (CD1/129Sv genetic back-
ground) 21 weeks of age before and after 2 mg/kg nicotine injection. The onset of the DAC (at
29 s after nicotine injection) is indicated by the arrowhead above the trace, and the offset of the
DAC is indicated by the arrowhead below the trace. B, Electroencephalograms during nicotine-
induced tonic–clonic seizures display large paroxysmal discharges with an ictal spike/wave
configuration. The trace shows an electroencephalogram from a heterozygous female CD1/
129Sv genetic background mouse 21 weeks of age that received an injection of nicotine. The
paroxysmal spiking activity starts 120 s after injection of 10 mg/kg nicotine. C, D, Recordings
from the VO (Ci, Di) and epidural electroencephalograms (Cii, Dii) from a female CD1/129Sv
genetic background heterozygous mouse 12 weeks of age after injection of nicotine (2 mg/kg)
and PTZ (70mg/kg). In Ci and Cii, the onset of the DAC is indicated by the arrowhead above the
trace, and the offset of the DAC is indicated by the arrowhead below the trace. The period of
animal handling andnicotine injection is indicated by the horizontal bar above the beginning of
the trace (C), and the period of animal handling and injection of PTZ is indicated by the horizon-
tal bar (D). In this experiment, PTZwas injected 30min after nicotine injection. E, An expanded
section of the recording in D marked by the asterisk. After nicotine injection, no activity was
evident in either the VO electrode or the epidural EEG electrodes during the DAC. In contrast,
after PTZ injection, spikes were evident on both the VO and epidural traces associated with
myoclonic activity.
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given injections of 6 mg/kg nicotine. As expected, LacZ staining
was prominent in the hippocampal dentate gyrus in all mice dis-
playing tonic–clonic seizures after administration of 6 mg/kg
nicotine (three of six heterozygous S248F mice and one in five
FTL single transgenic mice), indicating strong activation in this
region (Fig. 6C). LacZ staining in the hippocampus (Fig. 6A,B)
and other brain regions (data not shown) was at background
levels (i.e., the same as saline-injected mice) in FTL single trans-
genic mice, in all S248F/FTL double transgenic mice displaying
only the DAC in response to low-dose nicotine challenge, and in
all FTL single and S248F/FTL double-transgenic mice that dis-
played no clonic seizure or tremors after administration of high-
dose nicotine. Increased hippocampal dentate gyrus c-fos-
regulated gene expression was also sometimes seen after body
tremors alone (two of six S248F heterozygous mice given injec-
tions of 6 mg/kg nicotine). In summary, a total of five heterozy-
gous mice had a DAC alone (four after 2 mg/kg and one in re-
sponse to a 6 mg/kg injection), and yet no change in LacZ
expression was detected in the dentate gyrus or elsewhere in the
hippocampus.
The cohort of mice used in the study showed significant back-
ground cortical LacZ activity. Therefore, unlike the situation in
the hippocampus, it was not possible to exclude DAC-associated
activation of the neocortex in this experiment. There was no
increased signal-to-noise ratio in the basal ganglia in mice that
displayed the DAC.
Heterozygous S248F knock-in mice are relatively protected
from nicotine-induced seizures
A nicotine seizure dose–response relationship was determined
for WT and heterozygous mice in several genetic backgrounds
(CD1/129Sv, BL6 N1, and BL6 N5) (Table 1). Mice were scored
for body tremors, wild running, clonic seizures, and death asso-
ciated with clonic seizures. Forelimb dystonia and Straub tail
were not scored on the seizure scale because we had no direct
evidence from extensive EEG analysis and c-fos gene-regulated
activation studies to confirm that these behaviors were seizure
phenomena. The seizure scorewas analyzed using ordinal logistic
regression (McCullagh, 1980), with background (CD1/129Sv,
BL6 N1, and BL6 N5), genotype (wild type/heterozygous S248F
knock-in), and nicotine dose (2, 6, and 8mg/kg) as three explan-
atory variables. This model assumes only that the outcome vari-
able, seizure score is ordinal in nature. This analysis showed sta-
tistically significant effects of each of these three variables. The
data are consistent with the same underlying genotype difference
across genetic backgrounds and nicotine doses. The interaction
between background and genotype was not statistically signifi-
cant ( p  0.42). After testing for interac-
tions, a main effects model was fitted. This
showed that the main or average effect of
genotype was highly statistically signifi-
cant ( p  0.001); WT mice had more se-
vere seizures than heterozygous mice in all
genetic backgrounds. The effect of nico-
tine dosewas also statistically significant in
the expected direction (higher doses lead-
ing to more severe seizures; p  0.001).
There was also a statistically significant
difference of background overall ( p 
0.001). CD1/129Sv was the least affected,
BL6 N1 was more severe, and BL6 N5 was
the most severely affected. The pairwise
differences had the following p values:
CD1/129Sv versus BL6 N1, p 0.04; CD1/129Sv versus BL6 N5,
p 0.001; BL6 N1 versus BL6 N5, p 0.001.
The latency to seizure onset (defined as the point at which the
mouse lost its righting reflex) was independent of genotype but
did vary significantly with nicotine dose and genetic background,
with mice of the BL6 N5 background having more rapid-onset
seizures than CD1/129Sv backgroundmice as well asmore severe
seizures. At 6 mg/kg, latency for BL6 N5 mice was 92 2.7 s and
CD1/129Sv had a latency of 128 5.1 s, and at 8 mg/kg, BL6 N5
had a latency of 84 2.1 s and CD1/129Sv had a latency of 106
3.5 s ( p 0.001). Heterozygous S248F mice of all genetic back-
grounds examined displayed the DAC when given injections of
nicotine (2, 6, or 8 mg/kg). The DAC occurred before seizure
onset in cases in which convulsive doses of nicotine (i.e., 6 or 8
mg/kg) were used.
The DAC is not the result of complete loss of function of the
4-nAChR and is mecamylamine resistant
Ninety 4-nAChR knock-out (4/) mice (Ross et al., 2000)
(45 males and 45 females) and the same number of littermate
control mice on a hybrid 129SvJ/C57BL/6 genetic background
were given injections of 2, 6, and 8mg/kg nicotine. The DACwas
not seen in the 4/ mice at any nicotine dose. This is an
important observation given the results of our synaptosome assay
showing that at high agonist doses, the mutant receptor showed
impaired function. Ordinal logistic regression (McCullagh,
1980) was also used to analyze the knock-out data (Table 1); here
there was only one background, so the two explanatory variables
were genotype and nicotine dose. The effect of nicotine dose was
statistically significant in the expected direction (higher doses
leading to worse outcomes; p  0.001). The difference between
the genotypes was not statistically significant ( p  0.11); the
direction of the observed effect was that the homozygous knock-
out mice did worse than the WT mice. Collectively, these data
suggest (1) that the DAC is not the result of complete loss of
function of the4-nAChR subunit and (2) that nicotine-induced
seizures in WT mice are not 4-nAChR subunit mediated, be-
cause loss of this receptor subunit did not diminish nicotine-
induced seizures.
Pretreatment of heterozygous S248F BL6 N1 background mice
(n  9) with the nicotinic channel antagonist mecamylamine (0.5
mg/kg, i.p.) 10 min before administration of 8 mg/kg nicotine did
not disrupt the DAC in any manner, although it did completely
inhibit all seizure-like behavior (tremors, wild running, clonic sei-
zures, and death associated with clonic seizures were not seen). In
contrast, mice administered nicotine after saline pretreatment (n
6) had a typical spectrum of seizures seen with this dose of nicotine.
Figure 6. c-fos-regulated gene expression in the hippocampus of phenotypic WT and FTL/S248F double-transgenic mice
treatedwithnicotine.A, An FTL transgenicmouse that receivedan injectionof 2mg/kgnicotine showsnoprominent LacZ staining
in the hippocampus. An identical picture is seen in FTL/S248F double-transgenic mice that received an injection of saline (not
shown).B, C, A FTL/S248F double-transgenic mutantmouse displaying the DACwith 2mg/kg nicotine shows no LacZ staining in
the hippocampus (B), whereas both FTL-positive WT (shown) and FTL/S248F double-transgenic (not shown) mice show promi-
nent LacZ staining in the dendate gyrus of the hippocampus after sustaining a tonic– clonic seizure at a nicotine dose of 6mg/kg
(C). Scale bars, 250m.
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Two of the six mice experienced tremors and wild running (maxi-
mum score of 2) and three of six mice died in the setting of clonic
seizures (maximum score of 4) (Fisher’s exact test, p 0.002).
The anticonvulsant sodium channel blocker carbamazepine
blocks the dystonic component of the DAC
The anticonvulsant sodium channel blocker carbamazepine is
effective in the treatment of ADNFLE (Provini et al., 2000). We
administered S248F heterozygous mice carbamazepine (40–60
mg/kg, i.p.) before challenge with nicotine (1–2 mg/kg, i.p.) and
monitored the DAC. Carbamazepine at 40 mg/kg had no signif-
icant effect on ambulation, but at 60 mg/kg, it reduced ambula-
tory scores to 25%of baseline (data not shown).Mutantmice had
a dose-dependent attenuation of nicotine-induced forelimb dys-
tonia (Fig. 7) (z test, 0 mg/kg vs 60 mg/kg, p  0.006), but
nicotine-induced saccadic behavior and Straub tail responses
were present at both doses of carbamazepine tested (Fig. 7). Car-
bamazepine (60 mg/kg) completely ablated forelimb dystonia
produced in response to 1 mg/kg nicotine (Fig. 7). These data
confirm that the dystonic component of the DACwas reduced by
a drug that produces a therapeutic effect in human ADNFLE.
Although mice were partially sedated at 60 mg/kg carbamaz-
epine, other studies had shown that even extreme sedation does
not prevent the emergence of the DAC (data not shown).
The DAC is abolished by preinjection of a small dose
of nicotine
Although we believe that the S248F mouse represents a good
model for aspects of ADNFLE, a possible objection is that nico-
tine injections elicit ADNFLE-like behaviors (i.e., DAC) in S248F
mice but nicotine prevents and/or diminishes events in ADNFLE
patients. As in all studies of nicotinic receptors, however, one
must note that nicotine either activates or desensitizes receptors
depending on the concentration or dose administered. There are
at least two possible mechanisms. First, at relatively low nicotine
doses, ADNFLE-like behaviors may be suppressed because nico-
tinic receptors are inactivated by desensitization. Second, higher
nicotine doses may trigger behavioral responses such as the DAC
by widespread nicotinic receptor activation. To date, two reports
have shown the therapeutic benefit of nicotine in ADNFLE pa-
tients: Willoughby et al. (2003) reported an almost complete
elimination of seizures in an ADNFLE patient after treatment
with a nicotine patch (this therapeutic benefit continues in this
patient; J. Willoughby, personal communication), and the study
by Brodtkorb and Picard (2006) showed a significant inverse cor-
relation between tobacco use and nocturnal seizure frequency. In
both studies, the authors argue that nicotine acts by desensitizing
nicotinic receptors. It would be reasonable to postulate that
chronic nicotine exposure during the waking period may lead to
receptor desensitization through stages 2–4 of sleep at night,
when most ADNFLE events occur. In addition, both behavioral
actions of nicotinewere demonstrated in a knock-inmouse strain
engineered to express hypersensitive 4 nicotinic receptors
(L9A) (Fonck et al., 2005): nicotine either initiated behavioral
seizures (at 2 mg/kg) or prevented them (at 0.1 mg/kg, 10 min
before 2 mg/kg).
We performed similar experiments on heterozygous S248F
mice (n 9, three male and six female mice on a CD1/129 back-
ground). A dose of nicotine (0.1 mg/kg) too small to give the full
DACwas able to block the DACwhenmice were given injections
of 2mg/kg nicotine 10min later (none of ninemice displayed the
complete DAC). In contrast, saline preinjection had no effect on
the DAC in the same cohort of heterozygous mice (eight of nine
mice displayed the full DAC) (z-test, p  0.001) tested 1 week
later. These data are consistent with the published clinical studies
that suggest that chronic low-dose nicotine is effective in treating
ADNFLE by a mechanism of receptor desensitization.
The S248Fmutation confers mecamylamine resistance on
42-containing nAChRs
Previous studies show that 6 mutations make muscle nAChRs
resistant to channel block by QX-222 (Leonard et al., 1988).
Mecamylamine is a noncompetitive 42-nAChR antagonist
(Papke et al., 2001) and probably acts as a channel blocker (Gin-
iatullin et al., 2000). To determine whether the failure of
mecamylamine to block the DAC phenotype was caused by
mecamylamine resistance of the mutated S248F receptors, the
effects ofmecamylamine were studied on the ACh response of rat
42-nAChRs expressed in oocytes. The rat gene4(S252F)mu-
tation (which alignswith themouse4 S248Fmutation at theM2
6 position) conferred mecamylamine resistance on rat 42-
nAChRs expressed in oocytes (Fig. 8). We used an ACh concen-
tration (2 M) near the previously reported rat WT and
4(S252F)2 EC50 for ACh (Kuryatov et al., 1997; Figl et al.,
1998) and a mecamylamine concentration (0.5 M) near the
range of IC50 values previously reported for human 42-
nAChRs (Papke et al., 2001). As reported previously (Weiland et
al., 1996; Kuryatov et al., 1997; Bertrand et al., 1998; Figl et al.,
1998), the 4(S252F) mutation enhanced agonist-induced de-
sensitization. Successive applications of 2MACh at 3min inter-
vals had no significant effect on the peak WT response but re-
duced the peak mutant response significantly ( p  0.05) (Fig.
8A). To compensate for this effect, we applied ACh alone to the
oocytes three times and measured the ratios of the second- and
third-peak ACh responses to that of the first in a separate series of
experiments.We thendivided the corresponding responses in the
mecamylamine experiments by these ratios. As reported previ-
Figure7. Carbamazepine inhibits the dystonic component of theDAC.A–D, The percentage
of mice that displayed saccadic behavior (A), Straub tail (B), forelimb dystonia (C), and the
complete phenotype (D) after intraperitoneal administration of carbamazepine (CBZ) at 0
mg/kg (black bar), 40 mg/kg (gray bar), or 60 mg/kg (white bar), followed 22 min later with
either 1 or 2mg/kg nicotine intraperitoneally. *p 0.006, significantly different from0mg/kg
CBZ at the same nicotine dose. Data are expressed as a percentage of control mice that were
treated with vehicle. n 7–9 mice per group.
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ously (Giniatullin et al., 2000),mecamylamine persistently inhib-
ited the WT response. However, it produced no reduction in the
mutant response beyond that produced by cumulative agonist-
induced desensitization alone. The peak WT response in 0.5 M
mecamylaminewas 66 5% (n 5 oocytes) less than the control
and remained 51 4% (n 5) less after a 3min wash with saline
( p  0.05) (Fig. 8B). In contrast, after correcting for agonist-
induced cumulative desensitization, the mutant responses in 0.5
Mmecamylamine and after a 3 min wash were not significantly
different from the control response (Fig. 8B). Thus,
4(S252F)2-nAChRs expressed in oocytes were resistant to
mecamylamine block.
The activity of synaptosomal preparations were also investigated
to determine whether this resistance also occurs in heterozygous or
homozygous S248F knock-inmice using two assays shown above to
be affected by the S248F mutation. Dopamine release mediated by
CtxMII-resistantnAChRsandstimulatedbyACh(3M)wasmea-
sured using striatal synaptosomes fromWT, heterozygous, and ho-
mozygousmice. Synaptosomes fromS248Fmicewereperfused for5
min with CtxMII (50 nM) andmecamylamine (0–100M) before
exposure to ACh (3 M for 20 s) (Fig. 8C). Both the heterozygous
and homozygous mice are resistant to the effects of mecamylamine
for this activity. The 86Rb efflux properties of the S248F-nAChR
were investigated using synaptosomes from
thalamus (Fig. 8D) and cortex (Fig. 8E). For
both regions, synaptosomes fromWTmice
were blocked by considerably lower concen-
trations of mecamylamine than those from
either the heterozygous or homozygous
S248F mice. Similar results were obtained
for the dopamine release and the 86Rb ef-
flux assays using nicotine as agonist (data
not shown).
The concentration of mecamylamine
achieved in a mouse by the 0.5 mg/kg intra-
peritoneal dose is estimated to be 1 M
from an elimination time course for
[3H]mecamylamine in mouse brain (Col-
lins et al., 1994).This concentrationdoesnot
block the S248F-nAChR in the in vitro ex-
periments above. In conclusion, the in vitro
experiments confirm that a behavior, such
as theDAC,mediatedby theS248F-nAChRs
would be resistant to this level of the nAChR
blocker mecamylamine in vivo.
Discussion
Acute nicotine administration reveals a
highly penetrant and robust phenotype in
S248F knock-in mice not previously de-
scribed in other models of ADNFLE. The
DAC recapitulates two behaviors seen in
ADNFLE patients. In typical ADNFLE at-
tacks, sleep is interrupted by sudden eleva-
tion of the head and trunk and dystonic
posturing of the upper limbs (Scheffer et
al., 1995; Zucconi et al., 1997;Oldani et al.,
1998; Provini et al., 1999, 2000). The hu-
man video accompanying this report (Hu-
man ADNFLE video, available at www.
jneurosci.org as supplemental material)
shows an example of an ADNFLE attack.
The patient wakes from sleep in a startle,
sits upright, and looks forward. He turns
his head to the left and right and at times stares straight ahead.
The patient extends the arms forward in an asymmetrical dys-
tonic limbposture as the head-turningmovements continue. The
attack is brief, and the patient communicates at the end of the
attack. Dystonic upper-limb posturing and head and body
thrashing are described in detail in other patients in the literature
(Scheffer et al., 1995; Bertrand et al., 2005). The stereotypical
jerky exploratory-like darting thatwe observed in our S248Fmice
involves head and trunk movements analogous to those in
ADNFLE attacks. The stereotypical forelimb dystonia is probably
the most convincing correlate with the dystonic semiology of
ADNFLE: both mutant mice and humans display dystonic
twisting of the limbs, which may be tonic and sustained (as in
CD1/129Sv background S248F mice) or rhythmic (as in BL6 N5
background S248F mice). The attenuation of the dystonic com-
ponent of the DAC by carbamazepine suggests that the DAC
represents the murine equivalent of dystonic-predominant
ADNFLE attacks, because this drug effectively reduces the
frequency of NFLE attacks by 68% (Provini et al., 1999). In
accordance with some clinical studies (Willoughby et al., 2003;
Brodtkorb and Picard, 2006) showing a benefit of chronic low-
dose nicotine in reducing ADNFLE severity, and the inhibition of
Figure 8. The S248F mutant receptors are resistant to mecamylamine block. A, The current traces are voltage-clamp ACh
responses from oocytes expressing rat 42 WT receptors or 4(S252F)2 mutant receptors. The horizontal bars above the
traces show the timingof the 2MAChapplications, at 3min intervals. Three brief (10–30 s) ACh applications to theWT receptors
produced no significant change in the peak response (top left). In contrast, the same protocol resulted in significant cumulative
desensitization of the peakmutant response (top right).Mecamylamine (0.5M) persistently inhibited the peakWT response but
produced no further reduction in themutant response beyond that by produced byACh alone (bottom right). In the two lower sets
of traces, mecamylamine was present throughout the entire middle trace (second ACh application). B, The normalized peak WT
andmutant responses in 0.5Mmecamylamine and after a 3min wash with control saline corrected for cumulative desensitiza-
tion. After correction, mecamylamine had no significant effect on the mutant response. The asterisks denote a significant differ-
ence ( p 0.05) from control. C, Effect of mecamylamine on dopamine release from striatal synaptosomes of WT, heterozygous
(HT), and homozygous (HM) S248F mice. Synaptosomes were perfused for 5 min with the indicated concentration of
mecamylamine plusCtxMII (50 nM) and subsequently exposed to ACh (3M for 20 s) containing the indicated concentration of
mecamylamine. Data are expressed as percentage of response without mecamylamine. Control responses were as follows: WT
mice (n9), 15.61.0U; HTmice (n5), 10.81.9U; HMmice (n11), 7.81.6U.D, Effect ofmecamylamine on 86Rb
efflux from thalamic synaptosomes. The indicated concentration of mecamylamine was present for 2 min before and also during
the exposure to ACh (30 M for 5 s). Data are expressed as percentage of control response without mecamylamine. Control
responses (n 5mice per group)were as follows:WTmice, 20.6 1.5 U; HTmice, 15.0 1.2 U; HMmice, 4.9 0.9 U. E, Effect
of mecamylamine on 86Rb efflux from cortical synaptosomes. The indicated concentration ofmecamylaminewas present for 2
min before and also during the exposure to ACh (30M for 5 s). Data are expressed as percentage of control response without
mecamylamine. Control responses (n 5mice per group)were as follows:WTmice, 6.6 0.6 U; HTmice, 2.7 0.4 U; HMmice,
1.9 0.2 U.
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nicotine-induced behavioral seizures in L9A mice (Fonck et al.,
2005), we were also able to block the DAC by pretreatment with a
low dose of nicotine (0.1 mg/kg). The failure to detect an electro-
graphic correlate for the DAC was consistent with the absence of
ictal EEG activity in most ADNFLE attacks (Combi et al., 2004).
Surprisingly, heterozygous mice had less severe nicotine-
induced seizures thanWTmice of the same genetic background.
Indeed,4/mice had a normal nicotine-induced seizure pro-
file, confirming other reports (Damaj et al., 1999; Dobelis et al.,
2003) that nicotine-induced seizures in WT mice are not medi-
ated through the4-nAChR subunit; studies have implicated3,
4, and 5 subunits (Franceschini et al., 2002; Kedmi et al.,
2004). Finally, mecamylamine achieved complete abrogation of
nicotine-induced major motor seizures without inhibiting the
DAC, suggesting that the two processes may be mechanistically
different. Interestingly, this mecamylamine resistance is also
manifest in the agonist-induced currents for the S248F mutation
expressed in oocytes, as well as in agonist-induced ion flux and
transmitter release for synaptosomes from S248F mice.
A spectrum of severity in ADNFLEmouse models
Several other ADNFLE-relatedmodels have been reported. There
are two mouse strains with extreme gain-of-function mutations
in 4 at the M2–9 position, which have not been linked to AD-
NFLE. Although initially no spontaneous seizures were observed
in the L9mouse lines (Fonck et al., 2003, 2005), more recently,
we have identified spontaneous seizures (Fonck and Lester, 2006)
in a few L9A mice. These prolonged tonic–clonic seizures asso-
ciated with cortical c-fos activation seen only in young mice (age,
12–29 d) sometimes result in death. Severe motor seizures re-
stricted to a narrow postnatal time window would be atypical for
ADNFLE. Adult L9A mice (Fonck et al., 2005) were reported to
display low-dose nicotine-induced behavioral seizures not asso-
ciated with spike-and-wave EEG changes.
Two other 4 subunit ADNFLE knock-in strains have been
independently generated and studied: the Chrna4S252F (the
same mutation as reported here) and the 4L264 lines (Klaas-
sen et al., 2006). Both lines have spontaneous seizures of two
types: brief periods of behavioral arrest and prolonged hyperki-
netic motor seizures resembling bursts of wild running seen with
convulsive doses of nicotine (Franceschini et al., 2002). Sponta-
neous motor seizures occur commonly in both lines and are as-
sociated with high-voltage spiking activity on subdural EEG re-
cordings. Despite the frequency and severity of motor seizures,
premature death is not reported. The finding of electrographic
seizures in this model is consistent with reported electrographic
seizures occurring in ADNFLE (Scheffer et al., 1995; Hayman et
al., 1997; Phillips et al., 1998; Provini et al., 2000; Steinlein et al.,
2000). It should be noted that although ADNFLE is a disease of
non-REM sleep, the spontaneous seizures and EEG changes
noted in the Klaassen lines were not correlated to any sleep/wake
cycle.
A 2 subunit V287L (M2–22 position) ADNFLE mutant
mouse strain has also been reported briefly (Xu et al., 2006). The
few spontaneous seizures (2% of animals) have not yet been
systematically characterized.
The reported ADNFLE-related mice display a spectrum of
behavioral phenotypes that reflect the range ofmotor phenotypes
previously reported for ADNFLE (Scheffer et al., 1995). The hu-
man phenotypes include thrashing/hyperkinetic activity in the
minority (16 of 47) of cases and tonic stiffening in the majority
(36 of 47) of cases, 23 of which also had superimposed clonic
jerking. Our BL6N5 S248F knock-inmice display rhythmic fore-
limb dystonic posturing resembling the ADNFLE attacks de-
scribed in this clinical study.
In summary, the most severe spontaneous seizures are noted
in a small proportion of recently born juvenile L9A mice. The
Klaassen 4 strains display frequent spontaneous electrographic
major motor seizures. Infrequent as yet uncharacterized sponta-
neous seizure-like behaviors are seen in 2 subunit V287L mice,
whereas our S248Fmice and the adult L9Amice display no such
events. All strains reported to date display modest to low-dose
nicotine-induced behaviors that differ from what is seen in WT
mice. Importantly, these nicotine-induced ADNFLE like-
behaviors are EEG negative in the adult L9A, in our S248Fmice,
and in the 2 strain (C. Fonck, B. N. Cohen, J. Xu, H. A. Lester,
and S. F. Heinemann, unpublished data). The behavioral effects
of modest to low-dose nicotine in the Klaassen 4 strains were
described in a seizure scale, but associated EEG findings were not
reported.
Epilepsy or movement disorder?
If an epileptic seizure is defined as a transient occurrence of signs
and/or symptoms because of abnormal excessive or synchronous
neuronal activity in the brain (Fisher et al., 2005), then there are
only two possible explanations for failure to identify an electro-
graphic correlate to the DAC. First, perhaps the EEG paradigms
used in this study, and in previous studies that identified EEG
negative behavioral seizures, were not appropriately sensitive or
were not directed to the correct site in the brain. A systematic
unbiased and dense cortical and depth-electrode survey through-
out the entire mouse brainmay identify such a discrete focus and
address this caveat. This view is supported by observations in
human ADNFLE that single individuals may show a continuum
of paroxysmal events, beginning with arousals that lack distinc-
tive epileptiform features and evolving into dystonic attacks and
more violent events including frank tonic–clonic seizures with
overt epileptiform activity suggesting a common epileptic mech-
anism (Scheffer et al., 1995; Oldani et al., 1998; Provini et al.,
1999, 2000).
Second, perhaps the DAC is not an epileptic phenomenon but
rather represents a paroxysmalmovement disorder. A number of
studies have reported the coexistence of epilepsy and movement
disorders in the same individuals or in different individuals
within a family (Guerrini et al., 1999, 2002; Guerrini, 2001). In a
recent report, a mutation was identified in a calcium-sensitive
potassium channel in childhood-onset paroxysmal nonkinesi-
genic dyskinesia with absence epilepsy associatedwith rare tonic–
clonic seizures and generalized spike-wave complexes on electro-
encephalogram (Du et al., 2005). Of the 13 cases described, 7 had
paroxysmal dyskinesia alone, 5 had paroxysmal dyskinesia and
seizures, and 1 had only seizures. The clinical phenotype of a
genetically defined channelopathy can therefore be either epi-
lepsy or a paroxysmal movement disorder.
The influence of modifier genes/genetic backgroundmay also
explain the difference in the phenotype seen between our S248F
mice and the Klaassen lines. Two notable differences include the
CD1 background in our S248F mice and use of the J1 ES line by
Klaassen et al. (2006) versus our use of W9.5 cells. The potential
confounding effect of modifier genes on phenotype was under-
scored by a report on sodium channel 1 heterozygous knock-
out mice that model severe myoclonic epilepsy in infancy. The
mice showed a dramatically different phenotype depending on
genetic background: frequent spontaneous seizures in a C57BL/6
background and no seizures in a 129/SvJ background (Yu et al.,
2006). The late appearance and low penetrance of the dramatic
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juvenile spontaneous seizures in L9A mice in a line established
some years beforehand also argues for potential modifier gene
influence although an epigenetic effect is not excluded.
Conclusions
Our S248F line appears to predominantlymodel dystonic aspects
of ADNFLE semiology. Exploiting this line to identify channel
blockers (possibly related structurally tomecamylamine) that se-
lectively block S248Fmutant channel functionwould be useful in
treating carbamazepine-resistant cases of ADNFLE.
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